Logo

Ascentage Pharma Reports the US FDA’s Clearance to Commence the P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Leukemia

Share this
ascentage

Ascentage Pharma Reports the US FDA’s Clearance to Commence the P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Leukemia

Shots:

  • The US FDA has granted clearance to Ascentage Pharma for commencing a global registrational P-III study of olverembatinib (HQP1351) in H1’24
  • The open-label, randomized, registrational P-III study aims to evaluate the safety and efficacy of olverembatinib for the treatment of patients with CML-CP with/without T315I mutation
  • Olverembatinib (approved in the Chinese mainland) is a third-generation BCR-ABL inhibitor that targets BCR-ABL and a range of BCR-ABL mutants incl. the T315I mutation

Ref: Ascentage Pharma | Image: Ascentage Pharma

Related News:- Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions